[an error occurred while processing this directive] (none) [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive]

[ Home - Directory - Who's who - Mailing Lists - About Us - Sitemap - Social Events ]
[ Alumni - Management - Feedback - With Frills - Frames ]


startup: THIS WEDNESDAY: BioE2E @ WSGR: Valuation 2.0: How to Justify Biotech Value

DISCLAIMER: Any opinion expressed by a contributor is to be considered his/her own personal opinion, not the opinion of any other swiss-list member, the swiss-list website managers or the swiss-list committee.


[an error occurred while processing this directive]

startup: THIS WEDNESDAY: BioE2E @ WSGR: Valuation 2.0: How to Justify Biotech Value

From: BioE2E - Bay Area Biotech Entrepreneur Network <click for textversion of email address >
Date: Tue, 30 Sep 2003 01:11:17 -0700

Dear Startup List,

Come to a powerful, hot event reviewing the techniques for the coming
opening of the biotech market:

The details for our next event are now complete. see
http://www.bioe2e.org/2003/oct1.html

Valuation 2.0: How to Justify Biotech Value
Date: October 1, 2003 at 7:00pm
Location: Wilson Sonsini, 950 Page Mill Rd., Palo Alto, CA
Cost: $20 at the door

Companies sell parts (technology, developments) or totals to buyers (Big
Pharma, VCs, Investors). The market exercises a price pressure downwards,
whereas the company wants to maximize the proceeds
to move the entrepreneurial goals forward. Justification for price is
necessary from a fundamental perspective but is challenged with risk from
further development, which may lead to success or failure.
Therefore, companies need tools to consider such risks, but still
maximize the value, financial tools include option theory. In addition,
value drivers and soft values need to be established to help spread the
range of options in negotiations settings: The second best alternative.

* Trends in deal size and stage
* Technology vs. Product - License vs. Acquisition
* Methods of Valuation (What's the value ?): DCF, Decision tree, ROV & NPV
* Key drivers in valuation models: What makes the value big, what small,
what is not effecting the value
* How to value uncertainty and options, How to control risk and
uncertainty
* Risk & options as management decision tools: Managerial flexibility
* Alternative valuation approaches (gut, comparables)
* Immaterial value drivers: The bells & whistles
* Setting the valuation range
* Range of mobilities: Fields of Use, Customer Access, Geography
* Valuation issues (Risks)
* Accounting aspects
* Case study

Panelists:
* Nicola Campbell, Principal, BA Venture Partners
* Brian C. Cunningham, Partner, Cooley Godward
* Heath Lukatch, Managing Director, Piper Jaffray Ventures
* Pedro Santos, Director, Standard & Poors Corporate Valuation Service
(more detailed biographical information is online)

The event will be at Wilson Sonsini Goodrich and Rosati conference hall,
950 Page Mill Road, Palo Alto across from Genencor and just west of 650
Page Mill (the main WSGR building). Directions are at
the RSVP page.

It will help us for planning purposes if you RSVP to rsvp_at_bioe2e.org or
online. Please bring cash or check. We will not be accepting advance
payments or credit cards. Receipts will be available. If you
have any other questions, please contact us at info_at_bioe2e.org

See you then,
The BioE2E Steering Committee
http://www.bioe2e.org

+++++++ KILLMIME removed the following attachment(s):
+++++++++ part2: HTML document text

_______________________________________________
Startup mailing list
Startup_at_swiss-list.com
http://www.swiss-list.com/mailman/listinfo/startup
Received on Tue Sep 30 2003 - 17:24:30 PDT

[an error occurred while processing this directive]